We report on the clinical history of a 49-year-old female with metastatic pancreatic cancer. She was initially treated with standard chemotherapy as per current guidelines. She was found to have both a BRAF and P53 mutation, and received dabrafenib and trametinib with deep responses, both radiographically and biochemically (CA19-9). Her response has been more clinically relevant than responses in previous case reports of patients with BRAF-positive pancreatic cancer treated with targeted therapy. To the best of our knowledge, this is the first case report showing a dramatic therapeutic response to combination therapy with dabrafenib and trametinib in metastatic pancreatic cancer.
Case Rep Oncol 2020;13:1239–1243

中文翻译：

---

具有BRAF和P53突变的转移性胰腺癌：双重靶向治疗的治疗反应病例报告

我们报告了一位49岁女性转移性胰腺癌的临床病史。根据当前指南，她最初接受了标准化疗。发现她同时患有BRAF和P53突变，并接受了达布拉非尼和曲美替尼的放射线和生化反应均较深（CA19-9）。与先前靶向治疗的BRAF阳性胰腺癌患者的病例报告相比，她的反应在临床上更具相关性。据我们所知，这是第一例病例报告，显示对达巴非尼和曲美替尼联合治疗转移性胰腺癌有显着的治疗反应。
案件代表Oncol 2020; 13：1239–1243